eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies aimed at enhancing the human immune system's response to cancer and infectious diseases. The company's innovative TriMix technology specifically targets dendritic cells, which play a crucial role in initiating immune responses. By harnessing this technology, eTheRNA seeks to provide more effective and safer treatment options for patients with conditions such as melanoma and triple-negative breast cancer. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its research and development efforts. The company is dedicated to advancing the field of immunotherapy to improve patient outcomes.
Upstream Bio is a clinical-stage biotechnology company established in 2004 and headquartered in the United States. The company specializes in developing antibody therapies aimed at treating inflammatory diseases, with a primary focus on severe respiratory disorders, particularly severe asthma. Upstream Bio is advancing its lead candidate, verekitug, an antagonist that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine known to play a significant role in driving inflammatory responses. The approach of targeting TSLP positions Upstream Bio to address various immune-mediated conditions by intervening at a crucial point in the signaling pathways involved in inflammation.
CDR-Life is a Zurich-based biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology. Our facilities are located in the Bio-Technopark in Schlieren-Zurich, Switzerland
Aerium Therapeutics is discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 variants.
Endeavor BioMedicines is a clinical-stage company focused on creating innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). The company is developing a small-molecule inhibitor aimed at addressing the underlying causes of this disease. This potential therapy not only seeks to halt the progression of IPF but may also reverse its effects, thereby providing healthcare professionals with precision treatment options for this terminal condition. By targeting the root causes of the disease, Endeavor BioMedicines aims to improve patient outcomes and enhance quality of life for those affected by pulmonary fibrosis.
Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.
Rectify is developing disease-modifying precision therapies that restore ABC transporter function to address the underlying cause of serious genetic diseases. The company’s pipeline spans multiple therapeutic areas.
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, a novel aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its promising clinical candidates, CinCor Pharma seeks to gain marketing approval for innovative therapies that can effectively address unmet medical needs in these critical areas of health.
Thankful, Inc. is a company based in Los Angeles, California, that develops an artificial intelligence platform aimed at enhancing online customer service. The platform is designed to address and deflect a significant portion of repetitive customer inquiries, allowing customer care agents to focus on more complex issues. Its features include automated responses to questions, information gathering, ticket routing, and advanced script management. By improving the efficiency of customer service operations, Thankful's software helps eCommerce businesses increase customer satisfaction and reduce operational costs. The platform supports various written communication channels, providing customers with flexibility in how they engage with support services.
Anjarium Biosciences is a biotechnology company focused on engineering extracellular vesicles, particularly exosomes, to serve as advanced drug delivery systems for serious health conditions. By leveraging the natural communication network of the body, Anjarium transforms exosomes into effective therapeutic vehicles aimed at treating cancer and rare genetic diseases. Their proprietary Hybridosome® platform offers significant advantages in the design and application of these engineered exosomes, positioning the company at the forefront of developing targeted nanomedicines that could potentially improve patient outcomes in challenging therapeutic areas.
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company's lead programs include ALPN-101, an antagonist targeting the inducible T cell costimulator and CD28 pathways for autoimmune and inflammatory diseases, and ALPN-202, which combines programmed cell death protein ligand 1 and cytotoxic T-lymphocyte associated protein 4 antagonism with PD-L1 dependent CD28 costimulation for cancer treatment. Additionally, Alpine has a collaboration with Kite Pharma, Inc. to develop immunotherapies that target the immune synapse for cancer therapy. The company utilizes a proprietary platform to transform native immune system proteins into innovative, multi-targeted therapeutics.
Operator of a biopharmaceutical company intended to discover and develop next-generation medicines for neurodegenerative diseases. The company is focused on developing small-molecule activators of glucocerebrosidase and advanced programs targeting the innate immune system that can accelerate the progression of several neurological diseases, enabling healthcare professionals to transform the lives of patients with treatments for various ailments.
Lexeo Therapeutics is a clinical-stage biotechnology company specializing in genetic medicines. The company develops adeno-associated virus (AAV)-mediated therapies, primarily in collaboration with Weill Cornell Medicine’s Department of Genetic Medicine. Its pipeline includes treatments for both rare and non-rare monogenic diseases, as well as hereditary and acquired conditions. Lexeo Therapeutics aims to address high unmet medical needs across various patient populations, focusing on both preclinical and clinical gene therapy candidates. The company is committed to advancing its clinical programs towards commercialization while maintaining research partnerships to enhance its preclinical pipeline.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.
Synthekine Inc. is a biotechnology company focused on the development of engineered cytokine therapies and immunotherapies aimed at treating cancer and autoimmune disorders. Founded in 2018 and based in Menlo Park, California, Synthekine utilizes innovative platform technologies, including engineered partial agonists and orthogonal cell therapies, to create differentiated therapeutics. Its product pipeline features STK-009, an orthogonal ligand, and SYNCAR-001, a CAR-T therapy modified with orthogonal receptors. Additionally, the company is advancing STK-012, a partial agonist of IL-2, alongside Synthekines, which are designed to enhance signaling activities by combining cytokine receptors without relying on wild-type cytokines. Synthekine's approach is informed by immunological insights to ensure that its treatments are both safe and effective, with promising preclinical results indicating potential for improved efficacy and tolerability.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Theseus Pharmaceuticals
Series B in 2021
Theseus Pharmaceuticals is a Technology based company.
Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. It specializes in the development of vaccines using computationally designed virus-like particles (VLPs). The company's primary focus is on creating safe and effective vaccines to address significant unmet medical needs in the realm of infectious diseases, particularly life-threatening respiratory illnesses. One of its key vaccine candidates is IVX-121, aimed at protecting older adults from respiratory syncytial virus (RSV) disease. Icosavax leverages exclusive technology licensed from the Institute for Protein Design at the University of Washington to advance its innovative vaccine solutions.
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that utilize innovative platforms such as XTEN for half-life extension, XPAT for protease-activated T cell engagement, and ProTIA for immuno-oncology applications. Amunix aims to develop therapies that can effectively activate the immune system to target solid tumors, thereby improving patient outcomes. The company collaborates with various partners in the biotechnology and pharmaceutical sectors to leverage its proprietary technologies across multiple therapeutic areas. Founded in 2006 and headquartered in Mountain View, California, Amunix is committed to advancing breakthrough therapies to combat cancer.
Scorpion Therapeutics, Inc. is a biotechnology company focused on developing next-generation precision oncology technologies aimed at improving cancer treatment. Founded in 2020 and based in Boston, Massachusetts, the company specializes in creating precision oncology drugs that target known oncogenes, address currently undruggable cancer targets, and explore new therapeutic targets. By integrating advanced technologies in target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics seeks to expand the reach of precision medicine to a broader patient population. The company's approach is designed to unlock novel small-molecule drugs that can overcome the limitations of existing therapies, thereby enhancing treatment options for cancer patients.
Lexeo Therapeutics is a clinical-stage biotechnology company specializing in genetic medicines. The company develops adeno-associated virus (AAV)-mediated therapies, primarily in collaboration with Weill Cornell Medicine’s Department of Genetic Medicine. Its pipeline includes treatments for both rare and non-rare monogenic diseases, as well as hereditary and acquired conditions. Lexeo Therapeutics aims to address high unmet medical needs across various patient populations, focusing on both preclinical and clinical gene therapy candidates. The company is committed to advancing its clinical programs towards commercialization while maintaining research partnerships to enhance its preclinical pipeline.
Endeavor BioMedicines is a clinical-stage company focused on creating innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). The company is developing a small-molecule inhibitor aimed at addressing the underlying causes of this disease. This potential therapy not only seeks to halt the progression of IPF but may also reverse its effects, thereby providing healthcare professionals with precision treatment options for this terminal condition. By targeting the root causes of the disease, Endeavor BioMedicines aims to improve patient outcomes and enhance quality of life for those affected by pulmonary fibrosis.
Ikena Oncology is dedicated to bringing next generation oncology therapies to patients suffering from cancer. Ikena Oncology are committed to leveraging our unique understanding of the complex biologic pathways that drive the formation and spread of cancers to discover and develop novel, patient-directed therapies. Selecting patients for treatment in clinical studies with biomarkers we develop is at the core of our strategy.
Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead candidates, SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing Phase II trials for specific patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I trials for select advanced solid tumors. Syros employs a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to map gene regulatory circuits and modulate gene expression, positioning itself as a leader in gene control research. Additionally, Syros has established collaborations, including a target discovery agreement with Incyte Corporation focused on myeloproliferative neoplasms, and a licensing agreement with TMRC Co. Ltd. for tamibarotene's development and commercialization. Founded in 2011, Syros Pharmaceuticals aims to address significant unmet medical needs in oncology and beyond.
Imago BioSciences is a clinical-stage biotechnology company based in San Carlos, California, focused on developing innovative therapies for hematologic diseases, including leukemia and myelodysplastic syndromes. Established in 2012, the company specializes in small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme crucial for blood cell production in the bone marrow. Its lead candidate, Bomedemstat, is an orally available inhibitor of LSD1, being evaluated for its potential to modify the disease course in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers. Imago aims to translate advanced scientific insights into effective treatments that can significantly improve the quality and duration of life for patients facing these challenging conditions.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Scorpion Therapeutics, Inc. is a biotechnology company focused on developing next-generation precision oncology technologies aimed at improving cancer treatment. Founded in 2020 and based in Boston, Massachusetts, the company specializes in creating precision oncology drugs that target known oncogenes, address currently undruggable cancer targets, and explore new therapeutic targets. By integrating advanced technologies in target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics seeks to expand the reach of precision medicine to a broader patient population. The company's approach is designed to unlock novel small-molecule drugs that can overcome the limitations of existing therapies, thereby enhancing treatment options for cancer patients.
Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.
Chord Therapeutics SA is a clinical-stage biotechnology company based in Geneva, Switzerland, founded in 2014. The company focuses on developing innovative treatments for rare and severely disabling diseases, specifically targeting conditions such as neuromyelitis optica spectrum disorders (NMOSD), optic neuritis, transverse myelitis, and myasthenia gravis. Its lead drug candidate, CRD1, is currently advancing under orphan drug designation, aiming to provide solutions for patients with these life-threatening conditions.
Private Equity Round in 2020
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and based in San Mateo, California, the company concentrates on targeting dysregulated transcription factors and the associated transcriptional regulatory networks that contribute to cancer progression. Its lead candidate, entospletinib, is a selective inhibitor aimed at spleen tyrosine kinase for treating acute myeloid leukemia. Additionally, Kronos Bio is advancing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9, intended for the treatment of MYC-amplified solid tumors. The company employs advanced techniques, including high-throughput small-molecule microarrays and targeted protein degradation, to discover potent compounds that can effectively modulate challenging cancer targets.
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company's lead programs include ALPN-101, an antagonist targeting the inducible T cell costimulator and CD28 pathways for autoimmune and inflammatory diseases, and ALPN-202, which combines programmed cell death protein ligand 1 and cytotoxic T-lymphocyte associated protein 4 antagonism with PD-L1 dependent CD28 costimulation for cancer treatment. Additionally, Alpine has a collaboration with Kite Pharma, Inc. to develop immunotherapies that target the immune synapse for cancer therapy. The company utilizes a proprietary platform to transform native immune system proteins into innovative, multi-targeted therapeutics.
Sana Biotechnology is a biotechnology company focused on developing engineered cells as therapies for various diseases. Incorporated in 2018 and based in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company leverages recent scientific advancements to reprogram cells or replace damaged cells and tissues. Sana's mission is to create a new class of medicines that address unmet treatment needs across a wide range of therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Its pipeline includes several product candidates, such as SC291, SC262, SC255, and UP421, aimed at transforming the approach to disease treatment.
eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies aimed at enhancing the human immune system's response to cancer and infectious diseases. The company's innovative TriMix technology specifically targets dendritic cells, which play a crucial role in initiating immune responses. By harnessing this technology, eTheRNA seeks to provide more effective and safer treatment options for patients with conditions such as melanoma and triple-negative breast cancer. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its research and development efforts. The company is dedicated to advancing the field of immunotherapy to improve patient outcomes.
Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.
Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses.
Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.
FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. It specializes in developing innovative therapeutics for cancer treatment by targeting key molecular pathways involved in DNA replication stress. The company aims to create first-in-class compounds that represent a novel approach in the fight against cancer, focusing on drugging specific molecular targets associated with this replication stress. Through its research and development efforts, FoRx Therapeutics seeks to contribute to the advancement of targeted anticancer drugs within the healthcare industry.
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that utilize innovative platforms such as XTEN for half-life extension, XPAT for protease-activated T cell engagement, and ProTIA for immuno-oncology applications. Amunix aims to develop therapies that can effectively activate the immune system to target solid tumors, thereby improving patient outcomes. The company collaborates with various partners in the biotechnology and pharmaceutical sectors to leverage its proprietary technologies across multiple therapeutic areas. Founded in 2006 and headquartered in Mountain View, California, Amunix is committed to advancing breakthrough therapies to combat cancer.
Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare endocrine disorders. Founded in 2014 and based in Daly City, California, the company is primarily focused on its lead candidate, tildacerfont, which is being evaluated in Phase II clinical trials for classic congenital adrenal hyperplasia (CAH) in both adults and children. Tildacerfont aims to be the first non-steroidal treatment that enhances disease control while minimizing the reliance on steroids for managing CAH. Additionally, Spruce Biosciences is exploring tildacerfont's potential applications in treating polycystic ovary syndrome in women. The company has also entered a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications. Through its efforts, Spruce Biosciences seeks to significantly improve the quality of life for patients with rare endocrine disorders who have historically been underserved by medical advancements.
Anaconda Biomed, founded in 2015 and based in Barcelona, Spain, is an innovative medical technology company focused on developing advanced healthcare devices for the treatment of acute ischemic stroke (AIS). The company specializes in neuro-thrombectomy systems, notably the ANCD BRAIN™, a third-generation stented aspiration thrombectomy system. This system is designed to perform mechanical thrombectomies using a combination of a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. When deployed, the stent retriever expands to conform to the artery, effectively halting blood flow and enabling the complete extraction of thrombus without fragmentation. This technology aims to provide immediate treatment for stroke patients, significantly reducing the risk of fatality.
IFM Therapeutics specializes in developing small molecule medicines that target the innate immune system to address complex challenges in treating inflammatory and autoimmune disorders, as well as cancer. The company collaborates with academic partners to leverage expertise in innate immunity alongside experienced drug discovery professionals. Its subsidiary, IFM Due, focuses on discovering and developing antagonists of the cGAS/STING pathway, aiming to treat conditions such as inflammation, neuroinflammation, autoimmunity, and cancer. Additionally, IFM Discovery, a newly established incubator within the company, is engaged in advancing a portfolio of genetically validated targets for next-generation therapies addressing inflammation, neuroinflammation, autoimmunity, and fibrosis. Through these initiatives, IFM Therapeutics seeks to enhance immune response and improve the quality of life for patients facing serious health challenges.
Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and based in San Mateo, California, the company concentrates on targeting dysregulated transcription factors and the associated transcriptional regulatory networks that contribute to cancer progression. Its lead candidate, entospletinib, is a selective inhibitor aimed at spleen tyrosine kinase for treating acute myeloid leukemia. Additionally, Kronos Bio is advancing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9, intended for the treatment of MYC-amplified solid tumors. The company employs advanced techniques, including high-throughput small-molecule microarrays and targeted protein degradation, to discover potent compounds that can effectively modulate challenging cancer targets.
Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.
Prevail Therapeutics Inc. is a biotechnology company based in New York that specializes in developing gene therapies for neurodegenerative diseases. Founded in 2017 with support from The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, the company is focused on creating innovative adeno-associated virus (AAV)-based treatments. Its lead candidate, PR001, is currently undergoing Phase I/II clinical trials aimed at treating Parkinson's disease linked to GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is developing PR006 for frontotemporal dementia associated with GRN mutations and PR004 for various synucleinopathies. The company is dedicated to advancing therapies that can modify the course of these debilitating conditions.
Imago BioSciences is a clinical-stage biotechnology company based in San Carlos, California, focused on developing innovative therapies for hematologic diseases, including leukemia and myelodysplastic syndromes. Established in 2012, the company specializes in small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme crucial for blood cell production in the bone marrow. Its lead candidate, Bomedemstat, is an orally available inhibitor of LSD1, being evaluated for its potential to modify the disease course in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers. Imago aims to translate advanced scientific insights into effective treatments that can significantly improve the quality and duration of life for patients facing these challenging conditions.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
First Wave Bio, Inc. is a clinical-stage biotechnology company based in Ann Arbor, Michigan, established in 2015. The company focuses on developing gut-targeted small molecules aimed at treating inflammatory bowel disease (IBD) and other serious conditions. First Wave Bio's innovative solutions include a gut-restricted small molecule that can be administered either orally or rectally, specifically designed to treat ulcerative colitis and other forms of IBD. This approach aims to provide patients with more accessible and cost-effective treatment options, addressing the critical need for effective and safe therapies in this therapeutic area.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Andrew Alliance S.A. is a Swiss company based in Geneva, established in 2011, that specializes in developing and commercializing robotic solutions for the life sciences sector. The company aims to enhance laboratory efficiency by providing innovative tools for liquid handling, including the Andrew+ pipetting robot, which utilizes conventional electronic pipettes, and the Andrew portable liquid handling robot, designed for unattended operation. Its OneLab software allows users to create liquid handling protocols through a graphical interface, while the Andrew Assistant software facilitates the design and documentation of biological protocols. Andrew Alliance's products are engineered to improve ergonomics, minimize execution errors, and ensure traceability in laboratory processes. The company markets its robotic solutions directly and through distributors, serving clients both in Switzerland and internationally. The technology developed by Andrew Alliance integrates advanced robotics, vision systems, and software algorithms, aimed at replacing manual liquid handling methods in laboratories.
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and based in San Mateo, California, the company concentrates on targeting dysregulated transcription factors and the associated transcriptional regulatory networks that contribute to cancer progression. Its lead candidate, entospletinib, is a selective inhibitor aimed at spleen tyrosine kinase for treating acute myeloid leukemia. Additionally, Kronos Bio is advancing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9, intended for the treatment of MYC-amplified solid tumors. The company employs advanced techniques, including high-throughput small-molecule microarrays and targeted protein degradation, to discover potent compounds that can effectively modulate challenging cancer targets.
Attenua, Inc. is a biotechnology company based in San Mateo, California, founded in 2015. The company focuses on developing non-narcotic medicines specifically aimed at treating chronic cough and other chronic respiratory disorders. Recognizing the unmet needs in therapeutic areas often overlooked by larger pharmaceutical companies, Attenua seeks to uncover small molecule drugs that could significantly benefit patients. The team comprises experienced scientists and former advisors from major pharmaceutical firms, bringing extensive expertise in drug development. By prioritizing the discovery of innovative therapies, Attenua aims to improve the quality of life for individuals suffering from debilitating chronic conditions.
Prevail Therapeutics Inc. is a biotechnology company based in New York that specializes in developing gene therapies for neurodegenerative diseases. Founded in 2017 with support from The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, the company is focused on creating innovative adeno-associated virus (AAV)-based treatments. Its lead candidate, PR001, is currently undergoing Phase I/II clinical trials aimed at treating Parkinson's disease linked to GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is developing PR006 for frontotemporal dementia associated with GRN mutations and PR004 for various synucleinopathies. The company is dedicated to advancing therapies that can modify the course of these debilitating conditions.
Senti Biosciences is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative gene and cell therapies using its proprietary synthetic biology platform. Founded in 2016, the company aims to address complex diseases through advanced therapeutic solutions. Senti's technology includes engineered allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, which are designed to target and eliminate cancer cells while minimizing damage to healthy tissue. Among its product candidates are SENTI-202, a Logic Gated CAR-NK cell therapy intended for cancer treatment, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences operates as a resident company at Johnson & Johnson Innovation's JLABS in South San Francisco, collaborating with experts in synthetic biology and computation to advance its therapeutic developments.
ESSA Pharma Inc. is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada, established in 2009. The company specializes in developing novel therapies for the treatment of advanced prostate cancer, particularly metastatic castration-resistant prostate cancer (CRPC). ESSA is advancing its lead product candidate, EPI-7386, which is an oral small molecule designed to selectively block the amino-terminal domain of the androgen receptor (AR). This mechanism targets a critical component necessary for the growth and survival of prostate cancer cells, aiming to address the resistance mechanisms associated with current therapies. By focusing on this specific target, ESSA seeks to enhance the treatment options and improve survival outcomes for patients suffering from CRPC.
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Translate Bio is a clinical-stage biotechnology company based in Lexington, Massachusetts, that focuses on developing messenger RNA (mRNA) therapeutics aimed at treating diseases linked to protein or gene dysfunction. Since its founding in 2011, the company has been working on innovative treatments, including MRT5005, which is currently undergoing Phase I/II clinical trials for cystic fibrosis, and MRT5201, intended for the treatment of ornithine transcarbamylase deficiency. Translate Bio aims to create transformative medicines that address unmet medical needs in rare diseases.
ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Its primary product, IMU-838, is a selective immune modulator currently in Phase 2 clinical trials for ulcerative colitis, relapsing-remitting multiple sclerosis, and Crohn's disease. Additionally, the company is advancing IMU-935, an inverse agonist targeting RORgt, and IMU-856, which aims to restore intestinal barrier function in patients with conditions such as inflammatory bowel disease and irritable bowel syndrome. Immunic Therapeutics is headquartered in New York, New York, and seeks to provide effective treatment options for a range of chronic inflammatory conditions through its innovative drug development initiatives.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing novel small molecule therapeutics for unmet medical needs in autoimmunity and cancer. The company’s lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for multiple autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials for systemic lupus erythematosus. In addition to KZR-616, Kezar is advancing preclinical products, including KZR-TBD, aimed at treating oncology and autoimmune disorders. Founded in 2015, Kezar Life Sciences leverages insights into protein homeostasis, particularly the interplay between protein degradation and secretion, to drive its drug discovery efforts.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.
Anaconda Biomed, founded in 2015 and based in Barcelona, Spain, is an innovative medical technology company focused on developing advanced healthcare devices for the treatment of acute ischemic stroke (AIS). The company specializes in neuro-thrombectomy systems, notably the ANCD BRAIN™, a third-generation stented aspiration thrombectomy system. This system is designed to perform mechanical thrombectomies using a combination of a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. When deployed, the stent retriever expands to conform to the artery, effectively halting blood flow and enabling the complete extraction of thrombus without fragmentation. This technology aims to provide immediate treatment for stroke patients, significantly reducing the risk of fatality.
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Westlake Village, California. Founded in 2010, the company specializes in the development of innovative therapies in immunology and inflammation, particularly targeting dermatological conditions. Its lead candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials for atopic dermatitis, psoriasis, and pruritus. Additionally, Sienna is advancing SNA-001, a topical silver particle suspension in pivotal clinical trials aimed at treating acne and reducing light-pigmented hair. The company previously operated as Sienna Labs, Inc. and underwent significant financial restructuring, including a Chapter 11 bankruptcy filing in 2019, which transitioned to Chapter 7. Sienna Biopharmaceuticals aims to enhance patient outcomes and the practice of medicine through its targeted topical therapies.
Translate Bio is a clinical-stage biotechnology company based in Lexington, Massachusetts, that focuses on developing messenger RNA (mRNA) therapeutics aimed at treating diseases linked to protein or gene dysfunction. Since its founding in 2011, the company has been working on innovative treatments, including MRT5005, which is currently undergoing Phase I/II clinical trials for cystic fibrosis, and MRT5201, intended for the treatment of ornithine transcarbamylase deficiency. Translate Bio aims to create transformative medicines that address unmet medical needs in rare diseases.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies aimed at enhancing the human immune system's response to cancer and infectious diseases. The company's innovative TriMix technology specifically targets dendritic cells, which play a crucial role in initiating immune responses. By harnessing this technology, eTheRNA seeks to provide more effective and safer treatment options for patients with conditions such as melanoma and triple-negative breast cancer. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its research and development efforts. The company is dedicated to advancing the field of immunotherapy to improve patient outcomes.
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.
Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has built a diverse pipeline based on proprietary technology platforms developed in collaboration with institutions such as the University of Zürich and the California Institute of Technology. The company's offerings include Neuroseal, a biomaterial for dural sealing currently undergoing CE marking review in the EU, and MagnetOs Granules and Putty, approved for orthopedic, spinal, and dental applications in both the EU and the US. Kuros has an active clinical program, having conducted trials involving over 600 patients with promising results in various indications. Furthermore, Kuros has engaged in collaborations to advance its research, including work on CYT003 for oncology. Positioned for growth, Kuros is transitioning towards commercial operations, with plans for additional product approvals in the near future.
Editas Medicine is a clinical-stage company focused on developing innovative genome editing therapeutics to address serious diseases at the genetic level. Established in 2013 and headquartered in Cambridge, Massachusetts, with an additional site in Boulder, Colorado, the company leverages its proprietary CRISPR/Cas9 technology to create precise and corrective molecular modifications. This approach utilizes a protein-RNA complex, which includes the Cas9 enzyme and a guide RNA, to target and repair specific DNA sequences. Editas Medicine aims to translate its advances in genome editing into transformative human therapies, supported by a robust portfolio of patents and intellectual property that underpins its foundational technologies.
Translate Bio is a clinical-stage biotechnology company based in Lexington, Massachusetts, that focuses on developing messenger RNA (mRNA) therapeutics aimed at treating diseases linked to protein or gene dysfunction. Since its founding in 2011, the company has been working on innovative treatments, including MRT5005, which is currently undergoing Phase I/II clinical trials for cystic fibrosis, and MRT5201, intended for the treatment of ornithine transcarbamylase deficiency. Translate Bio aims to create transformative medicines that address unmet medical needs in rare diseases.
Median Technologies is a company that develops and markets software products and platforms for medical image analysis, focusing on oncology clinical trials and cancer screening. Founded in 2002 and based in Valbonne, France, it offers solutions such as iBiopsy, an AI-powered platform that aids in biomarker identification and patient profiling through CT scan similarity searches, and iSee, which facilitates image analysis and management in clinical trials. The company aims to standardize and automate the interpretation of medical images to enhance the diagnosis of cancer and evaluate treatment responses. Median Technologies serves both drug development and patient care markets, partnering with contract research organizations and Canon to deliver integrated imaging services and innovate new imaging technologies.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing novel small molecule therapeutics for unmet medical needs in autoimmunity and cancer. The company’s lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for multiple autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials for systemic lupus erythematosus. In addition to KZR-616, Kezar is advancing preclinical products, including KZR-TBD, aimed at treating oncology and autoimmune disorders. Founded in 2015, Kezar Life Sciences leverages insights into protein homeostasis, particularly the interplay between protein degradation and secretion, to drive its drug discovery efforts.
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics that target the disease-promoting microenvironment associated with fibrotic diseases and cancer. Founded in 2011 and based in Waltham, Massachusetts, the company works on innovative pharmaceutical preparations aimed at diagnosing and treating oncological and inflammatory conditions. Its drug development pipeline includes micro-environment activated therapeutics that utilize pleiotropic mechanisms to inhibit the synthesis and stabilization of extracellular matrix and to silence activated stromal cells. Through these novel approaches, XTuit Pharmaceuticals seeks to improve cancer therapies by addressing the tumor microenvironment effectively.
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Jounce Therapeutics is a clinical-stage immunotherapy company focused on developing innovative cancer treatments that harness the immune system to target and eliminate cancer cells. The company's lead product, vopratelimab, is a monoclonal antibody currently in Phase II trials for patients with non-small cell lung cancer and urothelial cancer, particularly those who have not responded to PD-1/PD-L1 inhibitors. Additionally, Jounce is advancing several other therapeutic candidates, including JTX-4014, an anti-PD-1 antibody intended for combination therapy, and JTX-1811, which aims to selectively deplete T regulatory cells in the tumor microenvironment. The company also develops JTX-8064, an antibody targeting a receptor on macrophages. Founded in 2013 by experts in immunobiology and cancer research, Jounce Therapeutics is headquartered in Cambridge, Massachusetts, and is committed to improving patient outcomes through its proprietary immunotherapy platform.
GelSight, Inc. specializes in advanced sensor technology solutions for precise surface measurements. The company has developed the GelSight benchtop scanner, which captures the surface geometry of various rigid materials with extraordinary detail, measuring at scales that span four orders of magnitude. This technology allows for visualization and measurement of 3D topography, revealing intricate details that are not visible to the naked eye, and providing dimensional measurements down to single-digit microns. GelSight's products are utilized across diverse sectors, including aerospace, electronics, ballistics, metrology, as well as in academic and forensic applications. Established in 2011 and headquartered in Waltham, Massachusetts, GelSight continues to innovate in the field of metrology, responding to the evolving surface measurement needs of its clients.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Median Technologies is a company that develops and markets software products and platforms for medical image analysis, focusing on oncology clinical trials and cancer screening. Founded in 2002 and based in Valbonne, France, it offers solutions such as iBiopsy, an AI-powered platform that aids in biomarker identification and patient profiling through CT scan similarity searches, and iSee, which facilitates image analysis and management in clinical trials. The company aims to standardize and automate the interpretation of medical images to enhance the diagnosis of cancer and evaluate treatment responses. Median Technologies serves both drug development and patient care markets, partnering with contract research organizations and Canon to deliver integrated imaging services and innovate new imaging technologies.
Andrew Alliance S.A. is a Swiss company based in Geneva, established in 2011, that specializes in developing and commercializing robotic solutions for the life sciences sector. The company aims to enhance laboratory efficiency by providing innovative tools for liquid handling, including the Andrew+ pipetting robot, which utilizes conventional electronic pipettes, and the Andrew portable liquid handling robot, designed for unattended operation. Its OneLab software allows users to create liquid handling protocols through a graphical interface, while the Andrew Assistant software facilitates the design and documentation of biological protocols. Andrew Alliance's products are engineered to improve ergonomics, minimize execution errors, and ensure traceability in laboratory processes. The company markets its robotic solutions directly and through distributors, serving clients both in Switzerland and internationally. The technology developed by Andrew Alliance integrates advanced robotics, vision systems, and software algorithms, aimed at replacing manual liquid handling methods in laboratories.
Paratek Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapies for life-threatening infectious diseases and other serious health conditions. The company’s lead products include NUZYRA, an oral and intravenous broad-spectrum antibiotic effective against community-acquired bacterial pneumonia and acute bacterial skin infections, and SEYSARA, a tetracycline antibiotic for treating moderate to severe acne vulgaris. Paratek’s research is anchored in tetracycline chemistry and biology, and the company actively collaborates with partners such as Zai Lab and Allergan, as well as academic institutions like Tufts University. Additionally, Paratek engages in cooperative research with the U.S. Army Medical Research Institute of Infectious Diseases to explore treatment options against infectious agents. Founded in 1996, Paratek continues to expand its focus on addressing severe diseases, including research into multiple sclerosis and systemic inflammatory conditions.
BioSilta Ltd. is a biotechnology company based in St. Ives, United Kingdom, focused on developing reagent-based microbial growth systems. Established in 2014, the company utilizes its proprietary EnBase technology platform to create EnPresso growth systems, which enhance the yield of high-quality biomolecules from microbial cultures. BioSilta offers products such as EnPresso B, aimed at improving recombinant protein yields from bacterial cultures, and EnPresso Y Defined, a tablet-based growth system for yeast cultures. In addition to these growth systems, the company supplies various accessories, including flasks, seals, and culture plates, catering primarily to the healthcare sector.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.
NeuroVision Imaging LLC is a neuroscience company that specializes in digital imaging and diagnostic solutions for Alzheimer’s disease and eye care. Founded in 2010 and based in Sacramento, California, the company focuses on developing diagnostic tests and biomarkers to detect and monitor amyloid pathology associated with Alzheimer’s disease. It has created a novel retinal imaging technology that allows for early detection and monitoring of amyloid-beta plaque accumulation in the brain through noninvasive eye imaging. This technology is currently being utilized in various clinical trials worldwide. Additionally, NeuroVision provides data aggregation services, biostatistics, and machine learning applications to analyze large datasets of images and biomarker data, aiming to enhance the understanding of neurodegenerative diseases. The company's services cater to clients both in the United States and internationally.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.
JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.
SpineVision is a spinal technology company focused on the development and marketing of implants and instrumentation for spinal treatment. The company offers spinal systems addressing a wide range of spinal pathologies including degenerative disc disease, deformity, cervical disorders, trauma and tumors. These products have been developed in collaboration with leading neurological and orthopedic surgeons which has resulted in over 20 patents.
SpineVision was founded in 1999 and is headquartered in Antony in France, with subsidiaries in Belgium, Italy, the United Kingdom, and the United States.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.
Translate Bio is a clinical-stage biotechnology company based in Lexington, Massachusetts, that focuses on developing messenger RNA (mRNA) therapeutics aimed at treating diseases linked to protein or gene dysfunction. Since its founding in 2011, the company has been working on innovative treatments, including MRT5005, which is currently undergoing Phase I/II clinical trials for cystic fibrosis, and MRT5201, intended for the treatment of ornithine transcarbamylase deficiency. Translate Bio aims to create transformative medicines that address unmet medical needs in rare diseases.
ONPATH Technologies provides scalable connectivity and monitoring solutions for high-performance networks. The company is a spin-out of Brocade Communications’ physical layer switch business. ONPATH’s Universal Connectivity System and HorizON Software platform automates data center and test infrastructure as an alternative to manual patching or mesh switching architectures. The platform is scalable from 8 to 4,096 non-meshed ports, independent of speed or protocol requirements. The company serves Cloud Networking, Test Automation, Network Monitoring, and Cyber Security application areas. It is based in Marlton, New Jersey.
Exenta, Inc. specializes in developing software tailored for the fashion and consumer goods industries. Founded in 2007 and based in New York, the company provides a comprehensive suite of solutions that includes enterprise resource planning, supply chain management, product lifecycle management, and shop floor control. Its software enhances operational efficiency by offering functionalities such as real-time data collection, workforce management, inventory oversight, and quality control. Additionally, Exenta’s tools support line and seasonal management, material tracking, sourcing, and cost management, enabling businesses to adapt swiftly to the fast-paced market demands. The company also provides design plug-ins that facilitate integration in design development and process management. Through these offerings, Exenta aims to streamline operations and drive revenue growth for its clients in the apparel and soft goods sectors.
HydroCision, Inc. is a medical device company based in North Billerica, Massachusetts, established in 1994. It specializes in the development and manufacturing of fluid jet surgical tools tailored for minimally invasive spine surgery. The company’s primary offerings include the SpineJet HydroDiscectomy System, which allows for the safe removal of tissue during discectomy procedures without thermal damage, and the TenJet System, designed for ultrasound-guided treatments of chronic tendon pain in various applications such as the shoulder and knee. HydroCision also provides the SpineJet Fusion System for preparing intervertebral disc spaces for graft implantation and the AlloJet system for debridement of donor bones. The company serves hospitals and physicians through its sales representatives, aiming to improve surgical outcomes by leveraging its proprietary water-jet technology. HydroCision was previously known as Surgijet Corporation until its name change in November 1996.